Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
An announcement from Quantum Biopharma ( (TSE:QNTM) ) is now available.
On November 26, 2025, Quantum BioPharma announced that CTV News’ investigative program W5 will feature a three-part series on the company’s allegations of stock market manipulation. The series, beginning today, investigates ‘stock spoofing,’ a tactic Quantum claims derailed their multiple sclerosis research, leading to a $700 million lawsuit against CIBC and RBC. This media exposure could impact Quantum’s industry positioning by highlighting the challenges faced due to alleged market manipulation, potentially influencing stakeholders and raising awareness about the illegal practice.
More about Quantum Biopharma
Quantum BioPharma Ltd. is a biopharmaceutical company focused on developing innovative treatments for neurodegenerative and metabolic disorders, as well as alcohol misuse disorders. Their lead compound, Lucid-MS, aims to prevent and reverse myelin degradation in multiple sclerosis. The company also holds strategic investments and retains a stake in Unbuzzd Wellness Inc., which markets an OTC product for alcohol misuse.
Average Trading Volume: 2,882
Technical Sentiment Signal: Sell
Current Market Cap: C$43.13M
See more data about QNTM stock on TipRanks’ Stock Analysis page.